Pediatrix Medical Group (NYSE:MD) Rating Increased to Buy at StockNews.com

Pediatrix Medical Group (NYSE:MD) was upgraded by equities research analysts at StockNews.com from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Wednesday.

Other equities analysts also recently issued research reports about the company. Macquarie started coverage on Pediatrix Medical Group in a research report on Monday, December 16th. They issued an “outperform” rating and a $18.00 price objective for the company. Truist Financial cut their price objective on Pediatrix Medical Group from $16.00 to $15.00 and set a “hold” rating for the company in a research report on Monday, January 6th. Mizuho lifted their price objective on Pediatrix Medical Group from $13.00 to $15.00 and gave the company a “neutral” rating in a research report on Tuesday, November 19th. Deutsche Bank Aktiengesellschaft lifted their price objective on Pediatrix Medical Group from $9.00 to $15.00 and gave the company a “hold” rating in a research report on Monday, November 4th. Finally, UBS Group lifted their price objective on Pediatrix Medical Group from $10.50 to $16.50 and gave the company a “neutral” rating in a research report on Tuesday, November 5th. Four analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to data from MarketBeat, Pediatrix Medical Group has an average rating of “Hold” and an average price target of $16.25.

Pediatrix Medical Group Price Performance

Pediatrix Medical Group stock opened at $14.01 on Wednesday. The company has a debt-to-equity ratio of 0.83, a current ratio of 1.42 and a quick ratio of 1.42. The company has a market capitalization of $1.20 billion, a PE ratio of -4.58, a price-to-earnings-growth ratio of 1.40 and a beta of 1.58. Pediatrix Medical Group has a one year low of $6.62 and a one year high of $16.41. The business has a 50 day simple moving average of $14.03 and a 200 day simple moving average of $11.95.

Pediatrix Medical Group (NYSE:MD) last posted its earnings results on Friday, November 1st. The company reported $0.44 EPS for the quarter, topping the consensus estimate of $0.37 by $0.07. The business had revenue of $511.20 million during the quarter, compared to the consensus estimate of $498.87 million. Pediatrix Medical Group had a positive return on equity of 12.79% and a negative net margin of 12.65%. Pediatrix Medical Group’s revenue was up .9% on a year-over-year basis. During the same quarter last year, the company earned $0.29 EPS. On average, sell-side analysts forecast that Pediatrix Medical Group will post 1.26 EPS for the current fiscal year.

Insider Buying and Selling at Pediatrix Medical Group

In other news, EVP Mary Ann E. Moore sold 8,108 shares of the business’s stock in a transaction dated Friday, November 8th. The stock was sold at an average price of $16.00, for a total value of $129,728.00. Following the sale, the executive vice president now directly owns 135,810 shares in the company, valued at $2,172,960. The trade was a 5.63 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Mark S. Ordan sold 27,600 shares of the company’s stock in a transaction dated Wednesday, November 13th. The stock was sold at an average price of $15.35, for a total value of $423,660.00. Following the sale, the director now owns 138,683 shares in the company, valued at $2,128,784.05. The trade was a 16.60 % decrease in their position. The disclosure for this sale can be found here. Insiders own 1.20% of the company’s stock.

Hedge Funds Weigh In On Pediatrix Medical Group

A number of institutional investors have recently bought and sold shares of the business. State Street Corp increased its stake in shares of Pediatrix Medical Group by 1.4% during the third quarter. State Street Corp now owns 3,540,791 shares of the company’s stock worth $41,038,000 after purchasing an additional 50,597 shares during the period. Nordea Investment Management AB boosted its holdings in shares of Pediatrix Medical Group by 51.6% in the 4th quarter. Nordea Investment Management AB now owns 263,633 shares of the company’s stock valued at $3,504,000 after purchasing an additional 89,739 shares in the last quarter. Barclays PLC boosted its holdings in shares of Pediatrix Medical Group by 302.9% in the 3rd quarter. Barclays PLC now owns 142,087 shares of the company’s stock valued at $1,646,000 after purchasing an additional 106,817 shares in the last quarter. Franklin Resources Inc. acquired a new stake in shares of Pediatrix Medical Group during the 3rd quarter valued at $598,000. Finally, Principal Financial Group Inc. boosted its holdings in shares of Pediatrix Medical Group by 14.1% during the 3rd quarter. Principal Financial Group Inc. now owns 513,618 shares of the company’s stock valued at $5,953,000 after acquiring an additional 63,581 shares in the last quarter. Institutional investors and hedge funds own 97.71% of the company’s stock.

About Pediatrix Medical Group

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.